Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral hexavalent reassortant rotavirus live attenuated vaccine (vero cell)
- Development stage
- Unknown
- Lead developer
- Wuhan Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The oral hexavalent reassortant rotavirus live attenuated vaccine (Vero cell) is a multivalent vaccine developed by the Wuhan Institute of Biological Products (WIBP), a subsidiary of China National Biotec Group (CNBG) and Sinopharm. The vaccine is produced using Vero cell culture technology and contains six human-bovine reassortant rotavirus strains. It is designed to provide broad protection against rotavirus gastroenteritis by targeting the most epidemiologically significant serotypes, including G1, G2, G3, G4, G8, and G9. Upon oral administration, the live-attenuated strains replicate in the intestinal tract to stimulate a robust mucosal and systemic immune response, inducing neutralizing antibodies against the viral VP7 and VP4 proteins. The vaccine was approved by China's National Medical Products Administration (NMPA) for the prevention of diarrhea caused by rotavirus infection in infants and young children.
- Other names
- 口服六价重配轮状病毒减毒活疫苗（Vero细胞）Hexavalent Rotavirus VaccineWIBP Hexavalent Rotavirus VaccineWIBP-RV6WIBP-RV-6WIBP-RV 6
02
Targets
VP7 (Outer capsid glycoprotein VP7)VP4 (Rotavirus VP4)
Beyond the preview
Go deeper on oral hexavalent reassortant rotavirus live attenuated vaccine (vero cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral hexavalent reassortant rotavirus live attenuated vaccine (vero cell).